Active, not recruitingNCT03932201

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bayer
Intervention: Damoctocog alfa pegol (Jivi, Bay94-9027)(drug)
Enrollment: 371 enrolled
Eligibility: All sexes
Timeline: 2019 – 2027

Study locations (29)

South Alabama Medical Science Foundation, Mobile, Alabama, United States
Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
University California Davis, Davis, California, United States
Orthopaedic Hospital DBA Orthopaedic Institute for Children, Los Angeles, California, United States
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange, California, United States
University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
Georgetown University, Washington D.C., District of Columbia, United States
Tulane University, New Orleans, Louisiana, United States
Regents of University of Minnesota, Minneapolis, Minnesota, United States
East Carolina University - Brody School of Medicine, Greenville, North Carolina, United States
Many locations, Multiple Locations, Belgium
Many locations, Multiple Locations, Brazil
Many locations, Multiple Locations, Canada
Many locations, Multiple Locations, Colombia
Many locations, Multiple Locations, Denmark
+14 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03932201 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials